novo nordisk semaglutide oral Novo's Wegovy: Dead-Cat Bounce or True Inflection? Novo Nordisk to protect US

Certain factors may increase the likelihood of experiencing bloating on GLP-1 therapy, including: Pre-existing gastrointestinal conditions such as irritable bowel syndrome (IBS), functional dyspepsia, or small intestinal bacterial overgrowth (SIBO) Rapid dose escalation without adequate titration periods Dietary factors , particularly high intake of fermentable carbohydrates (FODMAPs), fatty foods, or carbonated beverages Concurrent medications that affect gastrointestinal motility Patients should be aware that GLP-1 receptor agonists have been associated with more serious gastrointestinal adverse effects, including pancreatitis (inflammation of the pancreas) and gallbladder disease

Hepatology 60 , 20992108 (2014)

examined 11 studies involving patients over the age of 65 receiving GLP-1 receptor agonist treatments

Novo Nordisk didnt become the largest healthcare company in Europe solely due to the use of its medicine by diabetic patients